Share on StockTwits

AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating restated by investment analysts at Liberum Capital in a note issued to investors on Friday.

AZN has been the subject of a number of other recent research reports. Analysts at Citigroup Inc. reiterated a “buy” rating on shares of AstraZeneca plc in a research note on Friday. Separately, analysts at Jefferies Group reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Thursday. They now have a GBX 4,120 ($69.94) price target on the stock. Finally, analysts at Sanford C. Bernstein reiterated a “market perform” rating on shares of AstraZeneca plc in a research note on Wednesday. They now have a GBX 4,400 ($74.69) price target on the stock. Seven equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and seven have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of GBX 3,926.24 ($66.65).

Shares of AstraZeneca plc (LON:AZN) traded up 0.59% during mid-day trading on Friday, hitting GBX 4470.00. 4,340,777 shares of the company’s stock traded hands. AstraZeneca plc has a 1-year low of GBX 3028.50 and a 1-year high of GBX 5750.00. The stock has a 50-day moving average of GBX 4463.31 and a 200-day moving average of GBX 4002.. The company’s market cap is £56.367 billion.

AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.